Novo Nordisk UK strengthens no-deal Brexit plans

Gatwick, January 17 2019 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is committed to ensuring patients’ medicine supply is unaffected in the event of a ‘no-deal’ Brexit.

Novo Nordisk has planned for all future ‘no-deal’ contingencies. Our preparations include doubling UK stock to 16 weeks (around 4 months), which will be in place by the end of January. We will continue to build stock ahead of 29 March when we expect to have around two and a half times our normal stock levels (roughly 18 weeks). This significant increase builds on Novo Nordisk’s already robust plans for a ‘no deal’ scenario.

To further safeguard against potential border delays we have also secured pre-bookings of airfreight to bring essential medicines into the UK. We have scheduled monthly airfreight slots between April and July 2019 to ensure supply isn’t affected.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, “Our first commitment is to ensure that patients treated with our medicines remain unaffected in the event of a ‘no-deal’ Brexit. We believe our no-deal Brexit preparations are robust and we have taken all necessary steps to ensure continuity of supply to the UK patients we serve. This is evidenced by us more than doubling of stock levels to 16 weeks and securing airfreight slots from April.

“We continue to work closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations. We are also working collaboratively with the Department of Health to ensure continuity of supply, irrespective of the outcome of the Government’s Brexit negotiations.”

-END-

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.co.uk
Further information

Juliet Scott +44 (0)7557490116 zjl@novonordisk.com